Mark Murray

Mark Murray

Mark Murray joined FLG in 2014 and has also served on the firm’s Management Committee. 

Mark brings over 40 years  of experience in corporate finance in both public and private companies in the life science sector.

Mark helps companies by providing both corporate and financial strategic planning and execution, early to late-stage financings, M&A, licensing, OEM and coaching to senior management teams.  His functional experience includes finance, business development, IT, HR, facilities as well as a key member of senior management teams and working with Boards of Directors.

While at FLG, Mark has served as the CFO of Clarvista Medical, Grail Bio, Kedalion Therapeutics, Oculeve, Oyster Point Pharma Neuspera Medical, Presidio Medical and Route 92 Medical, among others.  Over the course of his career, Mark has raised more than $2 billion in equity financings, over $600 million in debt and M&A transactions in excess of $28 billion. 

Prior to FLG, Mark was Chief Financial Officer of OptiMedica Corporation, a ventured back company in ophthalmology, which was successfully acquired by Abbott Labs in 2013.  During his time at OptiMedica, Mark oversaw equity/debt financing greater than $90 million, sold part of the business (asset sale) in 2010 for $60 million and grew revenue for OptiMedica’s laser cataract business to nearly $20 million prior to the acquisition of OptiMedica by Abbott Labs for $400 million.

Previously to OptiMedica, Mark was Chief Financial Officer of Emphasys Medical, a ventured back interventional pulmonology company, in which he filed the company’s S-1 initial public offering and raised $15 in debt financing.

Previously, Mark spent 21 years with Guidant Corporation, including its predecessor Advanced Cardiovascular System and its successor Abbott Labs/Boston Scientific. Mark was part of Guidant’s senior management team and participated in its $1 billion IPO through its exit in 2006 for $27 billion (Abbott Labs/Boston Scientific).  During those 21 years, Mark led the finance team of Guidant’s Vascular Intervention group overseeing revenue growth from less than $20 million to over $1.3 billion; leading the business development team in strategic transactions that included M&A, drug in-licensing, OEM and equity investments; and overseeing the global installation of SAP. 

Mark started his career with international CPA firms of Ernst & Whinney and Main Hurdman. 

Mark holds a BS in business administration (accounting) from San Francisco State University.